{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T12:38:09Z","timestamp":1795005489809,"version":"4.9.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The tyrosine kinase inhibitor dasatinib is approved for Philadelphia chromosome\u2013positive leukemia, including chronic myeloid leukemia (CML). Although effective and well tolerated, patients typically exhibit a transient lymphocytosis after dasatinib uptake. To date, the underlying physiological process linking dasatinib to lymphocytosis remains unknown. Here, we used a small rodent model to examine the mechanism of dasatinib-induced lymphocytosis, focusing on lymphocyte trafficking into and out of secondary lymphoid organs. Our data indicate that lymphocyte homing to lymph nodes and spleen remained unaffected by dasatinib treatment. In contrast, dasatinib promoted lymphocyte egress from spleen with kinetics consistent with the observed lymphocytosis. Unexpectedly, dasatinib-induced lymphocyte egress occurred independently of canonical sphingosine-1-phosphate\u2013mediated egress signals; instead, dasatinib treatment led to a decrease in spleen size, concomitant with increased splenic stromal cell contractility, as measured by myosin light chain phosphorylation. Accordingly, dasatinib-induced lymphocytosis was partially reversed by pharmacological inhibition of the contraction-promoting factor Rho-rho associated kinase. Finally, we uncovered a decrease in spleen size in patients with CML who showed lymphocytosis immediately after dasatinib treatment, and this reduction was proportional to the magnitude of lymphocytosis and dasatinib plasma levels. In summary, our work provides evidence that dasatinib-induced lymphocytosis is a consequence of drug-induced contractility of splenic stromal cells.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009279","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T10:06:17Z","timestamp":1672394777000},"page":"2418-2430","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Dasatinib-induced spleen contraction leads to transient lymphocytosis"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-3580","authenticated-orcid":false,"given":"Ana","family":"Marcos-Jim\u00e9nez","sequence":"first","affiliation":[{"name":"1Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland"},{"name":"2Department of Immunology, Biomedical Research Institute La Princesa Hospital (IIS-IP), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-3378","authenticated-orcid":false,"given":"Daniela Claudino","family":"Carvoeiro","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-3363","authenticated-orcid":false,"given":"Nora","family":"Ruef","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cuesta-Mateos","sequence":"additional","affiliation":[{"name":"2Department of Immunology, Biomedical Research Institute La Princesa Hospital (IIS-IP), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-5785","authenticated-orcid":false,"given":"Emilia","family":"Roy-Vallejo","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, IIS-IP, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valle","family":"G\u00f3mez-Garc\u00eda de Soria","sequence":"additional","affiliation":[{"name":"4Department of Hematology, IIS-IP, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lagan\u00e1","sequence":"additional","affiliation":[{"name":"5Department of Radiology, IIS-IP, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4787-7806","authenticated-orcid":false,"given":"Lourdes","family":"del Campo","sequence":"additional","affiliation":[{"name":"5Department of Radiology, IIS-IP, Madrid, Spain"},{"name":"6Department of Medicine, School of Medicine, Universidad Aut\u00f3noma of Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[{"name":"7Department of Clinical Pharmacology, University Hospital La Princesa, Te\u00f3filo Hernando Institute, Universidad Aut\u00f3noma de Madrid, IIS-IP, Madrid, Spain"},{"name":"8Center for Biomedical Research Network on Liver and Digestive Diseases (CIBERehd), Health Research Institute Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-3268","authenticated-orcid":false,"given":"Gonzalo","family":"Villapalos-Garc\u00eda","sequence":"additional","affiliation":[{"name":"7Department of Clinical Pharmacology, University Hospital La Princesa, Te\u00f3filo Hernando Institute, Universidad Aut\u00f3noma de Madrid, IIS-IP, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[{"name":"7Department of Clinical Pharmacology, University Hospital La Princesa, Te\u00f3filo Hernando Institute, Universidad Aut\u00f3noma de Madrid, IIS-IP, Madrid, Spain"},{"name":"8Center for Biomedical Research Network on Liver and Digestive Diseases (CIBERehd), Health Research Institute Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-9586","authenticated-orcid":false,"given":"Jens V.","family":"Stein","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4085-3115","authenticated-orcid":false,"given":"Cecilia","family":"Mu\u00f1oz-Calleja","sequence":"additional","affiliation":[{"name":"2Department of Immunology, Biomedical Research Institute La Princesa Hospital (IIS-IP), Madrid, Spain"},{"name":"6Department of Medicine, School of Medicine, Universidad Aut\u00f3noma of Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"24","key":"2023061219031817400_bib1","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2023061219031817400_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"2023061219031817400_bib3","unstructured":"U.S. Food and Drug Administration. Home page. Accessed 27 April 2021. https:\/\/www.fda.gov\/."},{"issue":"23","key":"2023061219031817400_bib4","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"2023061219031817400_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"7","key":"2023061219031817400_bib6","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3390\/cancers14071805","article-title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"14","author":"Saleh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"17","key":"2023061219031817400_bib7","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023061219031817400_bib8","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1074\/mcp.M900285-MCP200","article-title":"Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics","volume":"8","author":"Pan","year":"2009","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"2023061219031817400_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1158\/2326-6066.CIR-16-0061-T","article-title":"Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models","volume":"5","author":"Hekim","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"2023061219031817400_bib10","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1158\/1535-7163.MCT-09-0151","article-title":"Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin","volume":"8","author":"Ceppi","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2023061219031817400_bib11","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1158\/0008-5472.CAN-08-2246","article-title":"Synergistic activity of the Src family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress","volume":"69","author":"Kopetz","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"2023061219031817400_bib12","doi-asserted-by":"crossref","first-page":"e0129663","DOI":"10.1371\/journal.pone.0129663","article-title":"Rapamycin enhances the anti-cancer effect of dasatinib by suppressing Src\/PI3K\/mTOR pathway in NSCLC cells","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"2023061219031817400_bib13","doi-asserted-by":"crossref","first-page":"e0212860","DOI":"10.1371\/journal.pone.0212860","article-title":"Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model","volume":"14","author":"Walker","year":"2019","journal-title":"PLoS One"},{"key":"2023061219031817400_bib14","unstructured":"ClinicalTrials.gov. ClinicalTrials.gov database search engine. Accessed 27 April 2021. https:\/\/clinicaltrials.gov\/."},{"issue":"9","key":"2023061219031817400_bib15","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","article-title":"Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res"},{"issue":"5","key":"2023061219031817400_bib16","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bjh.15702","article-title":"Phase I\/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma","volume":"184","author":"Umakanthan","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2023061219031817400_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"499","key":"2023061219031817400_bib18","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"issue":"5","key":"2023061219031817400_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2023061219031817400_bib20","doi-asserted-by":"crossref","first-page":"e002582","DOI":"10.1136\/jitc-2021-002582","article-title":"Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies","volume":"9","author":"Leclercq","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2023061219031817400_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"key":"2023061219031817400_bib22","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3389\/fphar.2019.01340","article-title":"Immediate effects of dasatinib on the migration and redistribution of na\u00efve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients","volume":"10","author":"Colom-Fern\u00e1ndez","year":"2019","journal-title":"Front Pharmacol"},{"issue":"9","key":"2023061219031817400_bib23","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/cncr.29933","article-title":"Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity","volume":"122","author":"Schiffer","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"2023061219031817400_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","article-title":"Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?","volume":"89","author":"Paydas","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"2023061219031817400_bib25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"2023061219031817400_bib26","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3389\/fphar.2019.01232","article-title":"Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection","volume":"10","author":"Climent","year":"2019","journal-title":"Front Pharmacol"},{"issue":"7253","key":"2023061219031817400_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature13814","article-title":"Dendritic cells control fibroblastic reticular network tension and lymph node expansion","volume":"514","author":"Acton","year":"2014","journal-title":"Nature"},{"issue":"7523","key":"2023061219031817400_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/514441a","article-title":"Relax and come in","volume":"514","author":"Vaahtomeri","year":"2014","journal-title":"Nature"},{"issue":"11","key":"2023061219031817400_bib29","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nrm2786","article-title":"Non-muscle myosin II takes centre stage in cell adhesion and migration","volume":"10","author":"Vicente-Manzanares","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2023061219031817400_bib30","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1128\/MCB.20.11.4106-4114.2000","article-title":"Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion","volume":"20","author":"Jung","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2023061219031817400_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2045-8118-10-7","article-title":"Live cell imaging techniques to study T cell trafficking across the blood-brain barrier in vitro and in vivo","volume":"10","author":"Coisne","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"2023061219031817400_bib32","doi-asserted-by":"crossref","first-page":"120450","DOI":"10.1016\/j.talanta.2019.120450","article-title":"Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS\/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring","volume":"208","author":"Koller","year":"2020","journal-title":"Talanta"},{"issue":"7600","key":"2023061219031817400_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature17655","article-title":"Normalizing the environment recapitulates adult human immune traits in laboratory mice","volume":"532","author":"Beura","year":"2016","journal-title":"Nature"},{"issue":"6","key":"2023061219031817400_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2009-11-254334","article-title":"Comprehensive analysis of lymph node stroma-expressed Ig superfamily members reveals redundant and nonredundant roles for ICAM-1, ICAM-2, and VCAM-1 in lymphocyte homing","volume":"116","author":"Boscacci","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2023061219031817400_bib35","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.immuni.2016.10.018","article-title":"The chemokine receptor CX3CR1 defines three antigen-experienced CD8\u00a0T cell subsets with distinct roles in immune surveillance and homeostasis","volume":"45","author":"Gerlach","year":"2016","journal-title":"Immunity"},{"key":"2023061219031817400_bib36","doi-asserted-by":"crossref","first-page":"15327","DOI":"10.1038\/ncomms15327","article-title":"Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy","volume":"8","author":"Kallert","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"2023061219031817400_bib37","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni.3296","article-title":"A\u00a0map of the distribution of sphingosine 1-phosphate in the spleen","volume":"16","author":"Ramos-Perez","year":"2015","journal-title":"Nat Immunol"},{"issue":"6","key":"2023061219031817400_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00007256-200232060-00002","article-title":"The human spleen during physiological stress","volume":"32","author":"Stewart","year":"2002","journal-title":"Sports Med"},{"issue":"21","key":"2023061219031817400_bib39","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1158\/1078-0432.CCR-16-0667","article-title":"Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner","volume":"23","author":"Kreutzman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023061219031817400_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2002-03-0841","article-title":"CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway","volume":"101","author":"Stein","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2023061219031817400_bib41","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"De Rooij","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2023061219031817400_bib42","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-15-0781","article-title":"Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in\u00a0vivo","volume":"21","author":"Herman","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2023061219031817400_bib43","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2015-02-626291","article-title":"L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in\u00a0vivo","volume":"126","author":"Lafouresse","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2023061219031817400_bib44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.immuni.2007.11.017","article-title":"S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress","volume":"28","author":"Pham","year":"2008","journal-title":"Immunity"},{"issue":"5","key":"2023061219031817400_bib45","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.immuni.2020.03.010","article-title":"Visualization of T cell migration in the spleen reveals a network of perivascular pathways that guide entry into T zones","volume":"52","author":"Chauveau","year":"2020","journal-title":"Immunity"},{"issue":"6972","key":"2023061219031817400_bib46","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"issue":"3","key":"2023061219031817400_bib47","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/imm.12469","article-title":"Human spleen microanatomy: why mice do not suffice","volume":"145","author":"Steiniger","year":"2015","journal-title":"Immunology"},{"issue":"4","key":"2023061219031817400_bib48","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1152\/jappl.2001.90.4.1623","article-title":"Selected contribution: role of spleen emptying in prolonging apneas in humans","volume":"90","author":"Schagatay","year":"2001","journal-title":"J\u00a0Appl Physiol"},{"issue":"6","key":"2023061219031817400_bib49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.immuni.2021.03.025","article-title":"Adrenergic regulation of the vasculature impairs leukocyte interstitial migration and suppresses immune responses","volume":"54","author":"Devi","year":"2021","journal-title":"Immunity"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2418\/2056795\/blooda_adv-2022-009279-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2418\/2056795\/blooda_adv-2022-009279-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T15:04:12Z","timestamp":1686582252000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/11\/2418\/493949\/Dasatinib-induced-spleen-contraction-leads-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009279","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]}}}